

Driving Innovations through collaboration

EBF Open symposium

Launch pad session

20 November 2019



Problem statement: How do we overcome hurdles to innovation?

- Have conventional routes to drive innovations are
- Are we willing to invest and take risk
- Do we have the right ecosystem and academia

What is EBF role if we are going to address these challenges?

and




Are our motivations aligned?

Pharma:

- Develop innovative therapies
- Approvals
- Drug to market

Manufactures:

- Novel technology solutions
- Sales (equipment / technologies)
- Understand customer needs



CROs:

- Interface with range of customers
- P&L
- Integral partners

Academia:

- Publications/ Grants
- Student enrolment
- Novel research

Where are the next break troughs coming from

Technological

- Analytical platform development
 - Need for high sensitivity platforms (e.g low abundance proteins)
 - Broad spectrum Proteomic \Longrightarrow targeted proteomics \Longrightarrow Targeted protein quantitation
 - Transcriptomic technologies and data interpretations tools
 - Patient centric sampling techniques
 - CRISP screens

Biological understanding

- Quantitative imaging technologies
- AI tools to understand disease biology
- Role of quantitative/ qualitative biomarkers
- Improve understanding Human Genome and implications to disease biology

New drug modalities

- Cell and gene therapy
- Therapeutic antibody technologies (fragments, mutli-domain...)
- Vaccine therapies

Role of public private partnerships and Charities

Innovative Medicines Initiative*

- Budget: 5.3M
- Participants: 3116
- Projects: 136
- Publications: >3800

Charitable funds

- Bill and Malinda Gates foundations
- Michael J. Fox foundations
- Cancer research charities
- HIV research charities
- EBF

Pharma / Academia/ Manufacture collaborations

| Good things can be achieved when we work together

Many companies have established collaboration with Academia

Student ships and talent development

PRAC: Pfizer analytical Research Center (Ghent and Tasmania)

Pharma investment into Academia in some case leading to spin offs

Should EBF play in the sand box?

What role may/can/should EBF play to driving innovative thought to benefit patients?

Questions?

Thanks!